Phase I clinical trial of Keytruda + Lymphir for recurrent solid tumors yields positive preliminary results

Elahere shows survival benefit in long-term analysis for ovarian cancer patients in phase III study

AbbVie announced the final analysis of the confirmatory phase III MIRASOL trial evaluating the efficacy and safety of Elahere in women with folate receptor alpha-positive platinum-resistant ovarian cancer compared to chemotherapy.

March 21, 2025

Vol.51 No.11

Clinical Roundup

Genmab’s Rina-S shows promise in treating advanced ovarian cancer

Genmab A/S announced on March 17 updated data from cohort B1 of the phase I/II RAINFOL-01 study of rinatabart sesutecan, an investigational folate receptor-alpha-targeted, TOPO1 antibody-drug conjugate that showed Rina-S 120 mg/m2 every three weeks resulted in a confirmed objective response rate of 55.6% (95% CI: 30.8-78.5) in heavily pre-treated ovarian cancer patients regardless of FRα expression levels.

March 21, 2025

Vol.51 No.11

Clinical Roundup

Immunovia completes second clinical validation of next-gen pancreatic cancer test

Immunovia announced results from the VERIFI study, the second clinical validation study of its next-generation pancreatic cancer test.

March 21, 2025

Vol.51 No.11

Drugs & Targets

FDA approves Keytruda combination for HER2 positive gastric or gastroesophageal junction adenocarcinoma expressing PD-L1 (CPS ≥1)

FDA granted traditional approval to Merck’s pembrolizumab (Keytruda) with trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy for the first-line treatment of adults with locally advanced unresectable or metastatic HER2-positive gastric or gastroesophageal junction adenocarcinoma whose tumors express PD-L1 (CPS ≥1).

March 21, 2025

Vol.51 No.11

Clinical Roundup

Rusfertide meets primary endpoint in phase III VERIFY trial for patients with polycythemia vera

The phase III VERIFY trial, in which phlebotomy-dependent patients with polycythemia vera were randomized to treatment with either rusfertide (PTG-300) or placebo, as an add-on to standard of care treatment, met its primary endpoint of proportion of patients achieving response.

March 07, 2025

Vol.51 No.09

In Brief

UH Cancer Center, Queen’s Health partner on Hawai‘i’s first on-campus cancer clinical center

The University of Hawai‘i Cancer Center and the Queen’s Health Systems will jointly develop oncology clinic space at the UH Cancer Center’s facilities in Kaka‘ako.

February 28, 2025

Vol.51 No.08

Phase I clinical trial of Keytruda + Lymphir for recurrent solid tumors yields positive preliminary results

YOU MAY BE INTERESTED IN

Elahere shows survival benefit in long-term analysis for ovarian cancer patients in phase III study

Genmab’s Rina-S shows promise in treating advanced ovarian cancer

Immunovia completes second clinical validation of next-gen pancreatic cancer test

FDA approves Keytruda combination for HER2 positive gastric or gastroesophageal junction adenocarcinoma expressing PD-L1 (CPS ≥1)

Rusfertide meets primary endpoint in phase III VERIFY trial for patients with polycythemia vera

UH Cancer Center, Queen’s Health partner on Hawai‘i’s first on-campus cancer clinical center

Renew today!

Subscriber content

Never miss an issue!

Login

Phase I clinical trial of Keytruda + Lymphir for recurrent solid tumors yields positive preliminary results

YOU MAY BE INTERESTED IN

Elahere shows survival benefit in long-term analysis for ovarian cancer patients in phase III study

Genmab’s Rina-S shows promise in treating advanced ovarian cancer

Immunovia completes second clinical validation of next-gen pancreatic cancer test

FDA approves Keytruda combination for HER2 positive gastric or gastroesophageal junction adenocarcinoma expressing PD-L1 (CPS ≥1)

Rusfertide meets primary endpoint in phase III VERIFY trial for patients with polycythemia vera

UH Cancer Center, Queen’s Health partner on Hawai‘i’s first on-campus cancer clinical center

Never miss an issue!

Login

FDA approves Keytruda combination for HER2 positive gastric or gastroesophageal junction adenocarcinoma expressing PD-L1 (CPS ≥1)